Payment overview · 2025
General Payments
$248.73
10 reported records · 6 companies
Healthcare provider profile · identity verified
Lori Taylor, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BUTLER, GA · NPI 1083264626
Verified facts
What the public records show
CMS Open Payments records show Lori Taylor, FNP-C received $248.73 in general payments during 2025 across 10 reported records.
Axsome Therapeutics, Inc. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Qulipta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.78 | 30.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.64 | 26.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.44 | 14.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.61 | 9.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.27 | 9.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.99 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.73 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $75.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 264 | 146 |
| Gabapentin | Gabapentin | 184 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 180 | 78 |
| Diclofenac Sodium | Diclofenac Sodium | 177 | 91 |
| Lisinopril | Lisinopril | 155 | 68 |
| Prednisone | Prednisone | 155 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 46 |
| Simvastatin | Simvastatin | 106 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 47 |
| Metformin Hcl | Metformin Hcl | 98 | 40 |
| Omeprazole | Omeprazole | 90 | 47 |
| Meloxicam | Meloxicam | 89 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 24 |
| Mounjaro | Tirzepatide | 79 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 50 |
| Furosemide | Furosemide | 74 | 42 |
| Losartan Potassium | Losartan Potassium | 74 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 60 |
| Alprazolam | Alprazolam | 61 | 14 |
| Potassium Chloride | Potassium Chloride | 61 | 29 |
| Trazodone Hcl | Trazodone Hcl | 60 | 29 |
| Carvedilol | Carvedilol | 59 | 22 |
| Ibuprofen | Ibuprofen | 58 | 42 |
| Mupirocin | Mupirocin | 58 | 43 |
| Ozempic | Semaglutide | 58 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 23 |
| Famotidine | Famotidine | 56 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 27 |
| Allopurinol | Allopurinol | 54 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 16 |
| Eliquis | Apixaban | 48 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 21 |
| Metformin Hcl Er | Metformin Hcl | 46 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 21 |
| Sertraline Hcl | Sertraline Hcl | 43 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 16 |
| Sucralfate | Sucralfate | 42 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 13 |
| Azithromycin | Azithromycin | 39 | 39 |
| Amoxicillin | Amoxicillin | 37 | 33 |
| Glipizide | Glipizide | 36 | 12 |
| Linzess | Linaclotide | 35 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 13 |
| Ondansetron Odt | Ondansetron | 30 | 21 |
| Fluconazole | Fluconazole | 28 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 14 |
| Methocarbamol | Methocarbamol | 27 | 22 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | 11 |
| Ketoconazole | Ketoconazole | 24 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Colchicine | Colchicine | 16 | 13 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.73 · 10 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, BREZTRI, Korlym, Ozempic, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error